Additionally, a recent study identified inhibitory receptor CD161 as an attractive novel target for ICI through single cell profiling of tumor-infiltrating T cells of patients with IDH-WT and IDH-mutant gliomas (7) (Figure 1). Here, KLRB1 is linked to neoplasm.